Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin Choy

Showing results (81-90 of 180) with videos related to

Pageof 18
Sort By:
Scientific Reports|March 7, 2017
Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11Yunfei Liao, Slim Sassi, Stefan Halvorsen, et al.
Scientific Reports|August 11, 2018
Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11Yunfei Liao, Slim Sassi, Stefan Halvorsen, et al.
Oncotarget|April 1, 2015
MicroRNA-155 expression is independently predictive of outcome in chordomaEiji Osaka, Andrew D Kelly, Dimitrios Spentzos, et al.
Sarcoma|November 27, 2018
SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing TherapyEdwin Choy, Karla Ballman, James Chen, et al.
Scientific Reports|January 22, 2024
Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11Yunfei Liao, Slim Sassi, Stefan Halvorsen, et al.
Sarcoma|September 20, 2019
Corrigendum to "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy"Edwin Choy, Karla Ballman, James Chen, et al.
Scientific Reports|June 17, 2015
CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcomaYan Gao, Yong Feng, Jacson K Shen, et al.
The Oncologist|July 22, 2016
The Width of the Surgical Margin Does Not Influence Outcomes in Extremity and Truncal Soft Tissue Sarcoma Treated With RadiotherapyRima Ahmad, Alex Jacobson, Francis Hornicek, et al.
Cancer|March 2, 2025
Adjuvant chemotherapy in localized, resectable extremity and truncal soft tissue sarcoma and survival outcomes - A systematic review and meta-analysis of randomized controlled trialsMegan H Goh, Marcos R Gonzalez, Hillary M Heiling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2024
Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue SarcomaGregory M Cote, Candace L Haddox, Edwin Choy, et al.
Pageof 18

Showing results (81-90 of 180) with videos related to

Sort By:
Pageof 18
Scientific Reports|March 7, 2017
Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11Yunfei Liao, Slim Sassi, Stefan Halvorsen, et al.
Scientific Reports|August 11, 2018
Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11Yunfei Liao, Slim Sassi, Stefan Halvorsen, et al.
Oncotarget|April 1, 2015
MicroRNA-155 expression is independently predictive of outcome in chordomaEiji Osaka, Andrew D Kelly, Dimitrios Spentzos, et al.
Sarcoma|November 27, 2018
SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing TherapyEdwin Choy, Karla Ballman, James Chen, et al.
Scientific Reports|January 22, 2024
Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11Yunfei Liao, Slim Sassi, Stefan Halvorsen, et al.
Sarcoma|September 20, 2019
Corrigendum to "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy"Edwin Choy, Karla Ballman, James Chen, et al.
Scientific Reports|June 17, 2015
CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcomaYan Gao, Yong Feng, Jacson K Shen, et al.
The Oncologist|July 22, 2016
The Width of the Surgical Margin Does Not Influence Outcomes in Extremity and Truncal Soft Tissue Sarcoma Treated With RadiotherapyRima Ahmad, Alex Jacobson, Francis Hornicek, et al.
Cancer|March 2, 2025
Adjuvant chemotherapy in localized, resectable extremity and truncal soft tissue sarcoma and survival outcomes - A systematic review and meta-analysis of randomized controlled trialsMegan H Goh, Marcos R Gonzalez, Hillary M Heiling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2024
Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue SarcomaGregory M Cote, Candace L Haddox, Edwin Choy, et al.
Pageof 18